212 related articles for article (PubMed ID: 34476406)
21. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial.
Eskandary F; Dürr M; Budde K; Doberer K; Reindl-Schwaighofer R; Waiser J; Wahrmann M; Regele H; Spittler A; Lachmann N; Firbas C; Mühlbacher J; Bond G; Halloran PF; Chong E; Jilma B; Böhmig GA
Trials; 2019 Jan; 20(1):37. PubMed ID: 30635033
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
Front Immunol; 2022; 13():839380. PubMed ID: 35493469
[TBL] [Abstract][Full Text] [Related]
23. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
24. Microvascular inflammation in early protocol biopsies of renal allografts in cases of chronic active antibody-mediated rejection.
Tsuji T; Yanai M; Itami H; Ishii Y; Akimoto M; Fukuzawa N; Harada H; Fukasawa Y
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():26-30. PubMed ID: 26031582
[TBL] [Abstract][Full Text] [Related]
25. Prognosis and Treatment for Active and Chronic Antibody-Mediated Rejection in Renal Transplant Recipients; Single Center Experience.
Yilmaz VT; Dandin O; Kisaoglu A; Avanaz A; Kamaci D; Toru HS; Demiryilmaz I; Koksoy S; Aydinli B; Kocak H
Transplant Proc; 2022 Sep; 54(7):1809-1815. PubMed ID: 35907695
[TBL] [Abstract][Full Text] [Related]
26. Serum Soluble B Cell-Activating Factor Is a Non-Invasive Biomarker of Antibody-Mediated Rejection in Kidney Allograft With Satisfactory Risk Stratification Performance But Negligible Diagnostic Value.
Wu S; Su X; Ye Q; Wei Y; Gao Y; Huang M; Chen Y; Wang J; Zhang Q; Fu Q; Li J; Wu C; Huang H; Xu B; Zhang H; Liu L; Wang C
Front Immunol; 2022; 13():869444. PubMed ID: 35493478
[TBL] [Abstract][Full Text] [Related]
27. Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
Okada M; Tomosugi T; Futamura K; Hiramitsu T; Goto N; Narumi S; Takeda A; Watarai Y
Transplant Proc; 2020 Dec; 52(10):3051-3057. PubMed ID: 32694058
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients.
Kim IK; Choi J; Vo A; Kang A; Steggerda J; Louie S; Haas M; Mirocha J; Cohen JL; Pizzo H; Kamil ES; Jordan SC; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 28929636
[TBL] [Abstract][Full Text] [Related]
29. Antibody-mediated rejection due to anti-HLA-DQ antibody after pregnancy and delivery in a female kidney transplant recipient.
Sagasaki M; Nakada Y; Yamamoto I; Kawabe M; Yamakawa T; Katsumata H; Mafune A; Katsuma A; Kobayashi A; Koike K; Koike Y; Miki J; Yamada H; Kimura T; Tanno Y; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():81-84. PubMed ID: 29968405
[TBL] [Abstract][Full Text] [Related]
30. A refractory case of subclinical antibody-mediated rejection due to anti-HLA-DQ antibody in a kidney transplant patient.
Fujimoto T; Nakada Y; Yamamoto I; Kobayashi A; Tanno Y; Yamada H; Miki J; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():81-5. PubMed ID: 26031594
[TBL] [Abstract][Full Text] [Related]
31. Six-year outcomes in broadly HLA-sensitized living donor transplant recipients desensitized with intravenous immunoglobulin and rituximab.
Kahwaji J; Jordan SC; Najjar R; Wongsaroj P; Choi J; Peng A; Villicana R; Vo A
Transpl Int; 2016 Dec; 29(12):1276-1285. PubMed ID: 27529314
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
[TBL] [Abstract][Full Text] [Related]
33. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
34. Comparison of high-dose IVIG and rituximab versus rituximab as a preemptive therapy for de novo donor-specific antibodies in kidney transplant patients.
Kim HW; Lee J; Heo SJ; Kim BS; Huh KH; Yang J
Sci Rep; 2023 May; 13(1):7682. PubMed ID: 37169835
[TBL] [Abstract][Full Text] [Related]
35. Eculizumab to treat antibody-mediated rejection in a 7-year-old kidney transplant recipient.
Chehade H; Rotman S; Matter M; Girardin E; Aubert V; Pascual M
Pediatrics; 2015 Feb; 135(2):e551-5. PubMed ID: 25624380
[TBL] [Abstract][Full Text] [Related]
36. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
Eskandary F; Regele H; Baumann L; Bond G; Kozakowski N; Wahrmann M; Hidalgo LG; Haslacher H; Kaltenecker CC; Aretin MB; Oberbauer R; Posch M; Staudenherz A; Handisurya A; Reeve J; Halloran PF; Böhmig GA
J Am Soc Nephrol; 2018 Feb; 29(2):591-605. PubMed ID: 29242250
[TBL] [Abstract][Full Text] [Related]
37. Case Report: Splenic Irradiation for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Allograft Recipients With
Zhu L; Guo Z; Sa R; Guo H; Li J; Chen G
Front Immunol; 2021; 12():661614. PubMed ID: 33936098
[TBL] [Abstract][Full Text] [Related]
38. IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up.
Billing H; Rieger S; Süsal C; Waldherr R; Opelz G; Wühl E; Tönshoff B
Transpl Int; 2012 Nov; 25(11):1165-73. PubMed ID: 22897111
[TBL] [Abstract][Full Text] [Related]
39. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
40. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
